Free Trial

Perspective Therapeutics (CATX) Stock Price, News & Analysis

Perspective Therapeutics logo
$3.60 +0.21 (+6.19%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$3.60 0.00 (0.00%)
As of 07/3/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Perspective Therapeutics Stock (NYSE:CATX)

Key Stats

Today's Range
$3.40
$3.69
50-Day Range
$2.16
$4.11
52-Week Range
$1.60
$16.55
Volume
511,203 shs
Average Volume
1.08 million shs
Market Capitalization
$267.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.56
Consensus Rating
Buy

Company Overview

Perspective Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
24th Percentile Overall Score

CATX MarketRank™: 

Perspective Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 804th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Perspective Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.18, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Perspective Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Perspective Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Perspective Therapeutics are expected to decrease in the coming year, from ($0.88) to ($1.20) per share.

  • Price to Book Value per Share Ratio

    Perspective Therapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Perspective Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.38% of the float of Perspective Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Perspective Therapeutics has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Perspective Therapeutics has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Perspective Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Perspective Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.38% of the float of Perspective Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Perspective Therapeutics has a short interest ratio ("days to cover") of 5.3.
  • Change versus previous month

    Short interest in Perspective Therapeutics has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Perspective Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    20 people have searched for CATX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Perspective Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Perspective Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.72% of the stock of Perspective Therapeutics is held by insiders.

  • Percentage Held by Institutions

    54.66% of the stock of Perspective Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Perspective Therapeutics' insider trading history.
Receive CATX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perspective Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CATX Stock News Headlines

Research Analysts Set Expectations for CATX Q2 Earnings
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

CATX Stock Analysis - Frequently Asked Questions

Perspective Therapeutics' stock was trading at $3.19 on January 1st, 2025. Since then, CATX stock has increased by 12.9% and is now trading at $3.60.

Perspective Therapeutics, Inc. (NYSE:CATX) announced its earnings results on Tuesday, November, 12th. The company reported ($0.21) EPS for the quarter, meeting analysts' consensus estimates of ($0.21). The company earned $0.37 million during the quarter. Perspective Therapeutics had a negative trailing twelve-month return on equity of 27.40% and a negative net margin of 4,096.66%.

Perspective Therapeutics's stock reverse split before market open on Monday, June 17th 2024.The 1-10 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CATX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Perspective Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Chevron (CVX).

Company Calendar

Last Earnings
11/12/2024
Today
7/05/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NYSE:CATX
Previous Symbol
NYSE:CATX
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.56
High Stock Price Target
$20.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+248.8%
Consensus Rating
Buy
Rating Score (0-4)
3.18
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46.51 million
Net Margins
-4,096.66%
Pretax Margin
-3,780.02%

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.67 per share
Price / Book
1.35

Miscellaneous

Free Float
65,209,000
Market Cap
$267.22 million
Optionable
Optionable
Beta
1.18
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:CATX) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners